Ploeg M, Aben KK, Kiemeney LA (2009) The present and future burden of urinary bladder cancer in the world. World J Urol 27:289
Article
PubMed
PubMed Central
Google Scholar
Prakash G, Pal M, Odaiyappan K, Shinde R, Mishra J, Jalde D et al (2019) Bladder cancer demographics and outcome data from 2013 at a tertiary cancer hospital in India. Indian J Cancer 56:54–58
Article
PubMed
Google Scholar
Burger M, Catto JW, Dalbagni G, Grossman HB, Herr H, Karakiewicz P et al (2013) Epidemiology and risk factors of urothelial bladder cancer. Eur Urol 63:234–241
Article
PubMed
Google Scholar
Babjuk M, Bohle A, Burger M, Capoun O, Cohen D, Comperat EM et al (2017) EAU guidelines on non muscle-invasive urothelial carcinoma of the bladder: update 2016. Eur Urol 71:447–461
Article
PubMed
Google Scholar
Chen SY, Du LD, Zhang YH (2010) Pilot study of intravesical instillation of two new generation anthracycline antibiotics in prevention of superficial bladder cancer recurrence. Chin Med J (Engl) 123:3422–3426
Google Scholar
Addeo R, Caraglia M, Bellini S, Abbruzzese A, Vincenzi B, Montella L et al (2010) Randomized phase III trial on gemcitabine versus mytomicin in recurrent superficial bladder cancer: evaluation of efficacy and tolerance. J Clin Oncol 28:543–548
Article
CAS
PubMed
Google Scholar
Han RF, Pan JG (2006) Can intravesical bacillus Calmette–Guerin reduce recurrence in patients with superficial bladder cancer? A metaanalysis of randomized trials. Urology 67:1216–1223
Article
PubMed
Google Scholar
Shelley MD, Wilt TJ, Court J, Coles B, Kynaston H, Mason MD (2004) Intravesical bacillus Calmette–Guerin is superior to mitomycin C in reducing tumour recurrence in high-risk superficial bladder cancer: a meta-analysis of randomized trials. BJU Int 93:485–490
Article
CAS
PubMed
Google Scholar
Bassi P (2002) BCG (Bacillus of Calmette–Guerin) therapy of high-risk superficial bladder cancer. Surg Oncol 11:77–83
Article
PubMed
Google Scholar
Saint F, Irani J, Patard JJ, Salomon L, Hoznek A, Zammattio S et al (2001) Tolerability of bacille Calmette–Guerin maintenance therapy for superficial bladder cancer. Urology 57:883–888
Article
CAS
PubMed
Google Scholar
Lamm DL (2000) Efficacy and safety of Bacillus Calmette–Guérin immunotherapy in superficial bladder cancer. Clin Infect Dis 31:s86-90
Article
PubMed
Google Scholar
DeHaven JI, Traynellis C, Riggs DR, Ting E, Lamm DL (1992) Antibiotic and steroid therapy of massive systemic bacillus Calmette–Guérin toxicity. J Urol 147:738–742
Article
CAS
PubMed
Google Scholar
Orihuela E, Herr HW, Pinsky CM, Whitmore WF Jr (1987) Toxicity of intravesical BCG and its management in patients with superficial bladder tumors. Cancer 60:326–333
Article
CAS
PubMed
Google Scholar
Berry DL, Blumenstein BA, Magyary DL, Lamm DL, Crawford ED (1996) Local toxicity patterns associated with intravesical bacillus Calmette–Guérin: a Southwest Oncology Group Study. Int J Urol 3:98–100
Article
CAS
PubMed
Google Scholar
Brausi M, Oddens J, Sylvester R, Bono A, Beek C, Andel G et al (2014) Side effects of Bacillus Calmette–Guérin (BCG) in the treatment of intermediate- and high-risk Ta, T1 papillary carcinoma of the bladder: results of the EORTC genito-urinary cancers group randomised phase 3 study comparing one-third dose with full dose and 1 year with 3 years of maintenance BCG. Eur Urol 65(1):69–76
Article
CAS
PubMed
Google Scholar
Lamm DL, van der Meijden PM, Morales A, Brosman SA, Catalona WJ, Herr HW et al (1992) Incidence and treatment of complications of bacillus Calmette–Guerin intravesical therapy in superficial bladder cancer. J Urol 147(3):596–600
Article
CAS
PubMed
Google Scholar
Koya MP, Simon MA, Soloway MS (2006) Complications of intravesical therapy for urothelial cancer of the bladder. J Urol 175:2004–2010
Article
PubMed
Google Scholar
Steg A, Adjiman S, Debré B (1992) BCG therapy in superficial bladder tumours: complications and precautions. Eur Urol 21(suppl 2):35–40
Article
PubMed
Google Scholar
Richard C, Lockyer W, Gillat DA (2001) BCG immunotherapy for superficial bladder cancer. J R Soc Med 94(6):316
Google Scholar
Perez-Jacoiste AMA, Fernandez-Ruiz M, Lopez-Medrano F, Lumbreras C, Tejido A, San Juan R et al (2014) Bacillus Calmette–Guerin (BCG) infection following intravesical BCG administration as adjunctive therapy for bladder cancer: incidence, risk factors, and outcome in a single-institution series and a review of the literature. Medicine (Baltimore) 93:236–254
Article
CAS
Google Scholar
Nieder AM, Sved PD, Stein JP, Skinnerb DG, Soloway MS (2005) Cystoprostatectomy and orthotopic ileal neobladder reconstruction for management of bacille Calmette–Guérin-induced bladder contractures. Urology 65:909–912
Article
PubMed
Google Scholar
Hameed A, Sezian N, Thwaini A (2007) Bladder contracture: Review for intravesical bacillus Calmette–Guerin complication. Can J Urol 14:3745–3749
CAS
PubMed
Google Scholar
Oates RD, Stilmant MM, Freedlund MC, Siroky MB (1988) Granulomatous prostatitis following bacillus Calmette–Guerin immunotherapy of bladder cancer. J Urol 140(4):751–754
Article
CAS
PubMed
Google Scholar
LaFontaine PD, Middleman BR, Graham SD Jr, Sanders WH (1997) Incidence of granulomatous prostatitis and acid-fast bacilli after intravesical BCG therapy. Urology 49(3):363–366
Article
CAS
PubMed
Google Scholar
Stilmant M, Siroky MB, Johnson KB (1985) Fine needle aspiration cytology of granulomatous prostatitis induced by BCG immunotherapy of bladder cancer. Acta Cytol 29:961–966
CAS
PubMed
Google Scholar
Harada H, Seki M, Shinojima H, Miura M, Hirano T, Togashi M (2006) Epididymo-orchitis caused by intravesically instillated bacillus Calmette–Guérin: genetically proven using a multiplex polymerase chain reaction method. Int J Urol 13(2):183–185
Article
PubMed
Google Scholar
Demers V, Pelsser V (2012) “BCGitis”: a rare case of tuberculous epididymo-orchitis following intravesical Bacillus Calmette–Guérin therapy. J Radiol Case Rep 6(11):16–21
PubMed
PubMed Central
Google Scholar
Rischmann P, Desgrandchamps F, Malavaud B, Chopin D (2000) BCG intravesical instillations: recommendations for side-effects management. Eur Urol 37(suppl 1):33–36
Article
PubMed
Google Scholar
Siskron FT 4th, Venable DD, Gonzalez E, Eastham JA (1997) Granulomatous mass in a nonrefluxing renal unit after bacillus Calmette–Guerin therapy for bladder cancer. J Urol 158(3 Pt 1):882–883
Article
PubMed
Google Scholar
Mody GN, Tran V, Landman J (2009) BCGosis: case report of intravesicular bacille Calmette–Guérin causing upper tract granulomas simulating a renal mass without evidence of ipsilateral vesicoureteral reflux. Urology 73(2):444.e9–444.e10
Article
Google Scholar
Squires FB, Coakley FV, Berg WJ, Panicek DM (1999) Bilateral renal masses after local Bacillus Calmette–Guerin therapy for postcystectomy ureteral cancer. Abdom Imaging 24(2):200–201
Article
CAS
PubMed
Google Scholar
Wada Y, Sugiyama Y, Kikukawa H, Kuwahara T, Takahashi W, Takamiya T et al (2004) Isolated renal tuberculosis following intravesical Bacillus Calmette–Guérin therapy for bladder cancer. Urol Int 72(3):257–260
Article
CAS
PubMed
Google Scholar
Al-Qaoud T, Brimo F, Aprikian AG, Andonian S (2015) BCG-related renal granulomas managed conservatively: a case series. Can Urol Assoc J 9(3–4):E200–E203
Article
PubMed
PubMed Central
Google Scholar
Tavolini IM, Gardiman M, Benedetto G, Bassi P (2002) Unmanageable fever and granulomatous renal mass after intracavitary upper urinary tract bacillus Calmette–Guerin therapy. J Urol 167(1):244–245
Article
CAS
PubMed
Google Scholar
Yusuke H, Yoshinori H, Kenichi M, Akio H (2006) Granulomatous balanoposthitis after intravesical Bacillus-Calmette–Guerin instillation therapy. Int J Urol 13(10):1361–1363
Article
PubMed
Google Scholar
Sharma V, Sethy P, Dogra P, Singh U, Das P (2011) Primary tuberculosis of glans penis after intravesical bacillus Calmette–Guerin immunotherapy. Indian J Dermatol Venereol Leprol 77(1):47–50
Article
CAS
PubMed
Google Scholar
Aljada IS, Crane JK, Corriere N, Wagle DG, Amsterdam D (1999) Mycobacterium bovis BCG causing vertebral osteomyelitis (Pott’s disease) following intravesical BCG therapy. J Clin Microbiol 37(6):2106–2108
Article
CAS
PubMed
PubMed Central
Google Scholar
Katz DS, Wogalter H, D’Esposito RF, Cunha BA (1992) Mycobacterium bovis vertebral osteomyelitis and psoas abscess after intravesical BCG therapy for bladder carcinoma. Urology 40(1):63–66
Article
CAS
PubMed
Google Scholar
Abu-Nader R, Terrell CL (2002) Mycobacterium bovis vertebral osteomyelitis as a complication of intravesical BCG use. Mayo Clin Proc 77(4):393–397
Article
PubMed
Google Scholar
Van Thiel RJ, Nossent GD, Tjon-Pian-Gi NP (1992) Articular complications of intravesical BCG treatment for bladder carcinoma. Br J Urol 70(4):446–447
Article
PubMed
Google Scholar
Kusakabe T, Endo K, Nakamura I, Suzuki H, Nishimura H, Fukushima S et al (2018) Bacille Calmette–Guerin (BCG) spondylitis with adjacent mycotic aortic aneurysm after intravesical BCG therapy: a case report and literature review. BMC Infect Dis 1(18):290
Article
Google Scholar
Seastedt KP, Ahmad U, Lau C, Weigel PR, Tsang HC, Hartman BJ et al (2015) Mycotic thoracic aortic aneurysm after intravesical Bacillus Calmette–Guérin treatment. Ann Thorac Surg 99(6):2210–2212
Article
PubMed
Google Scholar
Costiniuk CT, Sharapov AA, Rose GW, Veinot JP, Desjardinsc M, Brandys TM et al (2010) Mycobacterium bovis abdominal aortic and femoral artery aneurysms following intravesical bacillus Calmette–Guérin therapy for bladder cancer. Cardiovasc Pathol 19(2):e29–e32
Article
PubMed
Google Scholar
Holmes BJ, LaRue RW, Black JH 3rd, Dionne K, Parrish NM, Melia MT (2014) Mycotic aortic aneurysm due to intravesical BCG immunotherapy: clinical manifestations and diagnostic challenges. Int J Mycobacteriol 3(1):60–65
Article
PubMed
Google Scholar
Gupta RC, Lavengood R Jr, Smith JP (1988) Miliary tuberculosis due to intravesical bacillus Calmette–Guerin therapy. Chest 94(6):1296–1298
Article
CAS
PubMed
Google Scholar
Jasmer RM, McCowin MJ, Webb WR (1996) Miliary lung disease after intravesical bacillus Calmette–Guérin immunotherapy. Radiology 201(1):43–44
Article
CAS
PubMed
Google Scholar
Strich J, Brancato S, Dolan R, Maruf M, Siddiqui MR, Sanford T et al (2017) Case presentation: lung consolidation as sequelae of BCG sepsis after combined intravesical and intraurethral BCG. Urol Case Rep 13:152–153
Article
PubMed
PubMed Central
Google Scholar
Van Outryve SM, Francque SM, Gentens PA, De Pauw FF, Bogaert EV, Van Marck EA et al (2004) Bacillus Calmette–Guérin-induced granulomatous hepatitis in a patient with a superficial bladder carcinoma. Eur J Gastroenterol Hepatol 16(10):1027–1032
Article
PubMed
Google Scholar
Fradet V, Gaudreau C, Perrotte P, Côté J, Paquin JM (2007) Management of hepatic granulomatous tuberculosis complicating intravesical BCG for superficial bladder cancer. Can Urol Assoc J 1(3):269–272
PubMed
PubMed Central
Google Scholar
Dogan D, Zor M, Ozkisa T, Ayten O, Yigit N, Yavas I (2015) Mediastinal granulomatous lymphadenitis after intravesical bacillus Calmette–Guerin treatment mimicking distant metastasis of primary bladder carcinoma. Arch Bronconeumol 51(10):526–527
Article
PubMed
Google Scholar
Green DB, Kawashima A, Menias CO, Tanaka T, Redelman-Sidi G, Bhalla S et al (2019) Complications of intravesical BCG immunotherapy for bladder cancer. RadioGraphics 39:80–94
Article
PubMed
Google Scholar
Shoenfeld Y, Aron-Maor A, Tanai A, Ehrenfeld M (2001) BCG and autoimmunity: another two-edged sword. J Autoimmun 16:235–240
Article
CAS
PubMed
Google Scholar